BioRestorative shares surge 10.40% after-hours on positive Phase 2 data and FDA Phase 3 alignment.

BioRestorative Therapies (Nasdaq:BRTX) surged 10.40% in after-hours trading following the announcement of positive blinded Phase 2 data for BRTX-100, its hypoxic-cultured mesenchymal stem cell therapy, in treating chronic lumbar disc disease. The data, to be presented on March 28, 2026, showed meaningful improvements in pain and function scales across ~45 patients, alongside favorable safety and tolerability. The company also highlighted alignment with the FDA on Phase 3 trial design elements, including endpoints and statistical assumptions, during a recent Type B meeting, with no safety concerns raised. These developments underscore progress toward late-stage clinical readiness and potential commercialization of BRTX-100, a non-surgical regenerative therapy addressing a significant unmet medical need. The pre-market press release detailing results and the upcoming meeting presentation further amplified investor optimism.